Lipid abnormalities in kidney disease and management strategies - Wikidata - awgldk - TriplyDB

Lipid abnormalities in kidney disease and management strategies

Lipid abnormalities in kidney disease and management strategies

http://www.wikidata.org/entity/Q27024982

about

Soy-based renoprotection Vascular calcification, bone and mineral metabolism after kidney transplantation Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients.Sources of Mortality on Dialysis with an Emphasis on Microemboli.Chronic Kidney Disease and Lipid Disorders.Lipid lowering in renal disease.Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease.Creation of disease-inspired biomaterial environments to mimic pathological events in early calcific aortic valve disease.Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition.Oxidative Stress in Kidney Diseases: The Cause or the Consequence?Berberine Protects Against Palmitate-Induced Apoptosis in Tubular Epithelial Cells by Promoting Fatty Acid Oxidation.

P2860

Q26751544-C8CA6D01-E3D5-47BD-A2B6-43E463D5FEC4 Q26771400-F4B0C833-AC7F-4980-B975-BA957305E104 Q34536594-1253AF4C-A769-443A-ACFD-B4226689AEB4 Q38758014-4AEC62D5-0CB5-486A-9464-242D9857AB60 Q38928458-9783690D-40F2-4149-95DB-09279367C9CD Q41007423-0AAB9864-AAAD-4B72-BE90-AC4FF6721AA7 Q41690923-EC1FBF70-FD0F-4D0F-AB77-E0ADE01C7148 Q42688659-698206D8-3308-4721-BAA2-A362A1B761E0 Q47215469-4DBBF6C7-7157-458F-A9EC-C8CE8EEBF021 Q47768797-6CE9F6EF-ADC5-4BC5-9B5D-08F06F28FCC9 Q48163520-797BF90E-C20E-46B4-B804-B272C7F9E59F Q52661291-C527F8C7-8B7D-4550-9812-6073C902ECE2

P2860

Lipid abnormalities in kidney disease and management strategies

http://www.wikidata.org/entity/Q27024982

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Lipid abnormalities in kidney disease and management strategies

@ast

Lipid abnormalities in kidney disease and management strategies

@en

Lipid abnormalities in kidney disease and management strategies

@nl

type

label

Lipid abnormalities in kidney disease and management strategies

@ast

Lipid abnormalities in kidney disease and management strategies

@en

Lipid abnormalities in kidney disease and management strategies

@nl

prefLabel

Lipid abnormalities in kidney disease and management strategies

@ast

Lipid abnormalities in kidney disease and management strategies

@en

Lipid abnormalities in kidney disease and management strategies

@nl

P1433

Q27024982-D4AEBB47-4220-48F0-B409-CE5550B8F3F4

P1476

Q27024982-5F2CF2AE-7856-4B02-AF8C-5905C2B06FC2

P2093

Q27024982-2C884104-B9DF-4295-ACB3-B2E85C45E29B

P2860

Q27024982-07019044-1897-4FC7-A443-2E225DB7A110

Q27024982-09CD0AB8-A10C-4999-9B3A-8EB3293CFE20

Q27024982-0A9D6D14-71FC-419C-9283-565F6970DC9C

Q27024982-10D87808-C959-4AC8-92CF-025F247D2FD4

Q27024982-190C8342-A06B-4491-82BB-48C3BCA4433A

Q27024982-1FBD2BBB-B436-4EDB-A08D-1BA8696176FF

Q27024982-20330DC0-8D6E-43CB-B8E0-040B73A844D3

Q27024982-2181727B-BB5D-4E9A-959F-2FC412632A03

Q27024982-24833463-5510-43FD-8650-CD73605A6A04

Q27024982-261CAB83-42C1-4BD4-9545-A0016785598E

P304

Q27024982-9AEEECAC-93C1-4025-AEB2-E2BD0B1BE1CD

P31

Q27024982-E4069FAE-1865-4619-91D6-AC9F4DF8E642

P3181

Q27024982-2C9BAF72-2A0D-4AAE-9890-BE69ECD73F3D

P356

Q27024982-135676C8-D756-44C6-B75E-3928CE2917A6

P407

Q27024982-CCEC5DD7-FF6D-4527-8F98-5AB84F828DD1

P433

Q27024982-74385F90-1709-465F-B406-6996DFCEC38D

P478

Q27024982-96603F55-DAA4-43BD-8CAB-FCC384EF4487

P577

Q27024982-620D701D-3E10-4C56-859B-F2D3CDCD00E9

P5875

Q27024982-F413C245-9175-4D1D-96DE-9161CD4B4B69

P698

Q27024982-F528488B-6CAA-4B19-AC4A-953BF1B02B34

P932

Q27024982-91216972-B9A3-428D-ADF7-4C57D957054B

P3181

P356

P1433

World journal of nephrology

P1476

Lipid abnormalities in kidney disease and management strategies

@en

P2093

Vishwam Pandya

http://www.w3.org/2001/XMLSchema#string

P2860

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

HMG CoA reductase inhibitors (statins) for dialysis patients

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data.

Relationships between serum lipid, lipoprotein, triglyceride-rich lipoprotein, and high-density lipoprotein particle concentrations in post-renal transplant patients.

Effects of combination lipid therapy in type 2 diabetes mellitus.

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.

P304

83-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1525392

http://www.w3.org/2001/XMLSchema#string

P356

10.5527/WJN.V4.I1.83

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272097248

http://www.w3.org/2001/XMLSchema#string

P698

25664249

http://www.w3.org/2001/XMLSchema#string

P932

4317631

http://www.w3.org/2001/XMLSchema#string